IL79719A - Pharmaceutical composition comprising monoclonal antibodies binding determinants of gram negative bacteria and hybridoma cell lines producing the antibodies - Google Patents

Pharmaceutical composition comprising monoclonal antibodies binding determinants of gram negative bacteria and hybridoma cell lines producing the antibodies

Info

Publication number
IL79719A
IL79719A IL79719A IL7971986A IL79719A IL 79719 A IL79719 A IL 79719A IL 79719 A IL79719 A IL 79719A IL 7971986 A IL7971986 A IL 7971986A IL 79719 A IL79719 A IL 79719A
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
cell lines
negative bacteria
hybridoma cell
gram negative
Prior art date
Application number
IL79719A
Other languages
English (en)
Other versions
IL79719A0 (en
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/781,242 external-priority patent/US4777136A/en
Application filed by Univ California filed Critical Univ California
Publication of IL79719A0 publication Critical patent/IL79719A0/xx
Publication of IL79719A publication Critical patent/IL79719A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL79719A 1985-09-27 1986-08-14 Pharmaceutical composition comprising monoclonal antibodies binding determinants of gram negative bacteria and hybridoma cell lines producing the antibodies IL79719A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/781,242 US4777136A (en) 1985-09-27 1985-09-27 Monoclonal antibody reactive with Pseudomonas Aeruginosa
US06/855,878 US4918163A (en) 1985-09-27 1986-04-24 Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria

Publications (2)

Publication Number Publication Date
IL79719A0 IL79719A0 (en) 1986-11-30
IL79719A true IL79719A (en) 1991-06-10

Family

ID=27119830

Family Applications (1)

Application Number Title Priority Date Filing Date
IL79719A IL79719A (en) 1985-09-27 1986-08-14 Pharmaceutical composition comprising monoclonal antibodies binding determinants of gram negative bacteria and hybridoma cell lines producing the antibodies

Country Status (11)

Country Link
US (2) US4918163A (index.php)
EP (1) EP0217527B1 (index.php)
JP (1) JP2539797B2 (index.php)
KR (1) KR910002427B1 (index.php)
AU (1) AU606581B2 (index.php)
DE (1) DE3686931T2 (index.php)
ES (1) ES2004340A6 (index.php)
IE (1) IE59685B1 (index.php)
IL (1) IL79719A (index.php)
NZ (1) NZ217283A (index.php)
PH (1) PH26525A (index.php)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
DK172840B1 (da) * 1986-07-03 1999-08-09 Genetic Systems Corp Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c
US5521085A (en) * 1986-12-15 1996-05-28 Mitsui Toatsu Chemicals, Inc. Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
DE3786173T2 (de) * 1986-12-15 1993-12-16 Mitsui Toatsu Chemicals Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten.
AU1807188A (en) * 1987-04-10 1988-11-04 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US5888519A (en) * 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US5594113A (en) * 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
EP0374296B1 (en) * 1988-12-22 1995-02-01 Dade International Inc. Lipohaptens and use of carrier-bound lipohaptens in immunoassays
DE3843784A1 (de) * 1988-12-24 1990-06-28 Battelle Institut E V Verfahren zum nachweis von gramnegativen mikroorganismen sowie hierfuer geeignete dna-proben und antikoerper
JPH02283294A (ja) * 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
EP0485430B1 (en) 1989-08-01 1998-09-16 The Scripps Research Institute Methods and compositions for ameliorating the symptoms of sepsis
US5965695A (en) * 1990-05-15 1999-10-12 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5198339A (en) * 1990-07-13 1993-03-30 Board Of Regents, The University Of Texas System Method for detection of gram-negative bacterial lipopolysaccharides in biological fluids
CA2094588A1 (en) * 1990-10-22 1992-04-23 Carl R. Alving Lipid a composition as immunogenic agents to prevent or treat gram-negative bacterial infections
US5773280A (en) * 1992-03-20 1998-06-30 The Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5994088A (en) 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
US5233024A (en) * 1991-04-09 1993-08-03 The Brigham & Women's Hospital Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use
EP0586573B1 (en) * 1991-05-16 2001-12-19 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
NZ259636A (en) * 1992-12-18 1997-10-24 Molecular Rx Inc Hybridomas which produce monoclonal antibodies specific for multiple sclerosis and their use in diagnostic assays
US5545721A (en) * 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
EP0679083A4 (en) * 1992-12-21 1999-03-24 Ophidian Pharm Inc PREVENTION AND TREATMENT OF SEPTICEMIA.
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
EP0710118B1 (en) * 1994-04-20 1998-11-25 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US5807694A (en) * 1995-09-07 1998-09-15 Economic Innovation And Technology Council, University Of Manitoba Detection of salmonella enteritidis and other pathogenic microorganisms and monoclonal antibody useful therefor
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
RU2536209C2 (ru) * 1999-07-16 2014-12-20 Веракс Биомедикал, Инк. Способ и устройство для выявления бактериального заражения образца крови и ткани
AU2008202582C1 (en) * 1999-07-16 2012-04-05 Verax Biomedical, Inc. Method and kit immuno-detecting bacteria in blood and tissues
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP2865688A1 (en) 2002-03-01 2015-04-29 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
DE10247430A1 (de) * 2002-10-11 2004-04-29 Fresenius Hemocare Gmbh Verfahren zur Bestimmung des Gehalts an Endotoxinen in Flüssigkeiten
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US20070254322A1 (en) * 2006-05-01 2007-11-01 Romaschin Alexander D Complement-based analyte assay
US8715949B2 (en) * 2006-09-07 2014-05-06 The United States Of America, As Represented By The Secretary Of The Navy Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components
EP2523680A4 (en) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
DK2900277T3 (da) 2012-12-13 2022-04-04 Immunomedics Inc Doser af immunokonjugater af antistoffer og sn-38 til forbedret effektivitet og reduceret toksicitet
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US9913903B2 (en) 2015-08-06 2018-03-13 Grifols Worldwide Operations Limited Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
US10570194B2 (en) * 2015-08-06 2020-02-25 Grifols Worldwide Operations Limited Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS
CN110392570A (zh) 2017-03-27 2019-10-29 免疫医疗公司 用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4443549A (en) * 1981-10-19 1984-04-17 Molecular Genetics, Inc. Production of monoclonal antibodies against bacterial adhesins
US4428931A (en) * 1982-03-15 1984-01-31 Merck & Co., Inc. Bacterial toxoids and gram-negative immune globulin therefrom
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
FI69639C (fi) * 1982-07-02 1986-03-10 Orion Yhtymae Oy Preparat foer anvaendning vid klamydia-diagnostik
JPS5929622A (ja) * 1982-08-10 1984-02-16 Meiji Seika Kaisha Ltd モノクロ−ナル抗体、その製造法およびその用途
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4525453A (en) * 1982-10-26 1985-06-25 Eastman Kodak Company Process for rapidly differentiating between gram-negative and gram-positive microorganisms
US4574116A (en) * 1983-01-13 1986-03-04 The Board Of Trustees Of The Leland Stanford Jr. University Methods and cell lines for immortalization and monoclonal antibody production by antigen-stimulated B-lymphocytes
DE3303649A1 (de) * 1983-02-03 1984-08-09 Wacker-Chemie GmbH, 8000 München Unter ausschluss von wasser lagerfaehige, bei zutritt von wasser bei raumtemperatur zu elastomeren vernetzende massen
JPH0776240B2 (ja) * 1983-05-06 1995-08-16 ベロス グル−プ エンドトキシンコア−と反応性のモノクロ−ナル抗体
US5057598A (en) * 1983-05-06 1991-10-15 Centocor, Inc. Monoclonal antibodies reactive with endotoxin core
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US4525465A (en) * 1983-10-07 1985-06-25 Nippon Kayaku Kabushiki Kaisha Water-insoluble biospecific absorbent containing argininal derivative
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4617264A (en) * 1983-11-04 1986-10-14 Syntex (U.S.A.) Inc. Pretreatment method and composition
WO1985002685A1 (en) * 1983-12-12 1985-06-20 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4683196A (en) * 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
US4596769A (en) * 1984-03-05 1986-06-24 Temple University Monoclonal antibodies to peptidoglycan and methods of preparing same
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
US4646465A (en) * 1984-06-22 1987-03-03 Suiseki Fujimoto Method of inoculating mushroom basidiospores seed basidiospore bed for inoculation, culture container for seed basidiospore bed, and boring apparatus for host wood for inoculation
FI853395L (fi) * 1984-09-05 1986-03-06 Cetus Corp Monoklonala antikroppar som blockerar gram-negativ bakterieendotoxin.
JP2691708B2 (ja) * 1984-09-26 1997-12-17 住友製薬株式会社 ヒトモノクローナル抗体およびその製法
JPS61130300A (ja) * 1984-11-27 1986-06-18 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　レランド　スタンフオ−ド　ジユニア　ユニバ−シテイ ヒトモノクロ−ナル抗体
AU597877B2 (en) * 1984-12-26 1990-06-14 Teijin Limited Anti-pseudomonas aeruginosa human monoclonal antibody
CA2300446C (en) * 2000-03-10 2009-05-19 Stan Mcclean Beverage brewing apparatus having automatic and semi-automatic brewing modes

Also Published As

Publication number Publication date
EP0217527A3 (en) 1989-02-08
AU606581B2 (en) 1991-02-14
EP0217527A2 (en) 1987-04-08
NZ217283A (en) 1991-07-26
US4918163A (en) 1990-04-17
DE3686931T2 (de) 1993-04-29
JP2539797B2 (ja) 1996-10-02
KR910002427B1 (ko) 1991-04-22
AU6323686A (en) 1987-04-02
IE59685B1 (en) 1994-03-23
US5484591A (en) 1996-01-16
ES2004340A6 (es) 1989-01-01
US4918163B1 (index.php) 1993-08-17
DE3686931D1 (de) 1992-11-12
IL79719A0 (en) 1986-11-30
EP0217527B1 (en) 1992-10-07
JPS62228295A (ja) 1987-10-07
PH26525A (en) 1992-08-07
IE862546L (en) 1987-03-27
KR870003195A (ko) 1987-04-15

Similar Documents

Publication Publication Date Title
IL79719A (en) Pharmaceutical composition comprising monoclonal antibodies binding determinants of gram negative bacteria and hybridoma cell lines producing the antibodies
US5035994B1 (en) Human stem cells and monoclonal antibodies
US5130144B1 (en) Human stem cells and monoclonal antibodies
IL67721A (en) Hybridoma cell lines,their preparation and their use for the production of human monoclonal antibodies
IL76142A (en) Monoclonal antibody specific to a human carcinoma tumor-associated antigen kc-4,hybrid cell lines producing the same,pharmaceutical compositions containing them and methods for the use thereof
EP0205405A3 (en) Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
IL87535A0 (en) Cell lines and monoclonal antibodies
AU2782789A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
AU579812B2 (en) Cell lines and their use for the production of proteins
IL88160A0 (en) Cell lines and monoclonal antibodies
JPS57181895A (en) Bound book and manufacture of bound book
IL76247A0 (en) Monoclonal antibodies to glycoconjugates,their production,their use and pharmaceutical compositions containing them,hybridoma cell lines secreting said antibodies and their preparation
EP0174204A3 (en) Gram-negative bacterial endotoxin blocking monoclonal antibodies and cells producing the same and formulations containing the same, and the production of all thereof
AU6373286A (en) Auto-anti-idiotypic monoclonal antibodies to steroid receptals and uses thereof
AU550364B2 (en) Immunogen of lidocaine-protein conjugate and antibodies derived therefrom
AU8407091A (en) Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies
EP0285511A3 (en) Monoclonal antibodies and their uses
ZA867342B (en) Monoclonal antibodies binding determinants of grams negative bacteria
IL85974A0 (en) Human monoclonal antibodies binding determinants of gram negative bacteria
EP0159025A3 (en) Monoclonal antibody specific to human alpha2-plasmin
JPS6471482A (en) Cell line and antiepiglycanin monoclonal antibody produced thereby
EP0306680A3 (en) Monoclonal antibodies to anti-thrombin binding substance, and their uses
GB2176802B (en) Monoclonal anti-human igg4 antibodies, their production and use
DE3276537D1 (en) Culture of anaerobic bacteria
IL72924A (en) Preparations for use in solid phase immunoassays comprising monoclonal antibodies covalently embedded in their immobilized hybridoma cells

Legal Events

Date Code Title Description
FF Patent granted
RH Patent void